what was the first glp 1 agonist glp-1_analogs [TUSOM The Impact of GLP-1 Receptor

Natural killer cell activity also increased twofold in the high-dose group

This review synthesizes current evidence linking microbiota alterations to Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and strokeincluding post-stroke cognitive impairment (PSCI), as well as major depressive disorder (MDD), bipolar disorder (BD), anxiety disorders, post-traumatic stress disorder (PTSD), and chronic fatigue syndrome (CFS)

North America leads the global market for BWFI, holding approximately 41.7% market share and a valuation near USD 0.51 billion in 2024

Cardiovascular disease(CVD) is prevalent among people with diabetes